[Federal Register Volume 89, Number 30 (Tuesday, February 13, 2024)]
[Notices]
[Page 10081]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02880]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Closed Meeting

    Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the 
following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended, and the Determination of the Director, Office of 
Strategic Business Initiatives, Office of the Chief Operating Officer, 
CDC, pursuant to Public Law 92-463. The grant applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.
    Name of Committee: Disease, Disability, and Injury Prevention and 
Control Special Emphasis Panel (SEP)--SIP24-004, Gauging Men's Reaction 
to Relabeling of GG1 Prostate Cancer and Understanding of Pathology 
Reports.
    Date: May 8, 2024.
    Time: 10 a.m.-6 p.m., EDT.
    Place: Teleconference/Web Conference.
    Agenda: To review and evaluate grant applications.
    For Further Information Contact: Natalie Brown, M.P.H., Scientific 
Review Officer, National Center for Chronic Disease Prevention and 
Health Promotion, Centers for Disease Control and Prevention, 4770 
Buford Highway, Mailstop S106-3, Atlanta, Georgia 30341-3717. 
Telephone: (404) 639-4601; Email: [email protected].
    The Director, Office of Strategic Business Initiatives, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-02880 Filed 2-12-24; 8:45 am]
BILLING CODE 4163-18-P